An official website of the United States government
Belgian Case-control Study on Bladder Cancer
Study Name: Belgian Case-control Study on Bladder Cancer
Principal Investigators:
Maurice Zeegers
Frank Buntinx
Additional researchers: Eliane Kellen
Institution/s:
Acad.Huisartsgeneeskunde, Catholic University of Leuven (KUL), Belgium
Comprehensive Cancer Institute Limburg, Belgium
Institution/s address:
Acad.Huisartsgeneeskunde,
KUL
Kapucijnenvoer 33 Blok J
3000 Leuven, Belgium
Tel 32/(0)16 33 74 93
Key References:
Kellen E., et al. Int J Cancer. 2006 May 15;118(10):2572- 8.
Kellen E., et al.. Int J Urol. 2006 Sep;13(9):1180-4.
Kellen E., et al.. Cancer Lett. 2007 Jan 8;245(1-2):51-60
Study Design: Population-based case control
Matching factors: None
Country: Belgium
ICD-0-3 morphology codes: 81203
Follow up of cases? No
Expected time of follow-up? N.A.
Urinary Bladder ICD-0-3 morphology codes: Transitional cell carcinoma (81203); Papillary carcinoma (81303); Squamous cell carcinoma (80703); Adenocarcinoma (81403); Leiomyosarcoma (88903)
| Cases | Controls | |
|---|---|---|
| Years of enrollment | 2003-2005 | 2003-2005 |
| Source population | Cancer registry | Population |
| Response rate (enrolled/eligible) | Not known | 26% |
| Total number enrolled | 200 | 386 |
| Subjects with DNA | 200 | 386 |
| Ethnic origin | 100% Caucasian | 100% Caucasian |
| Age: mean (range) | 67.67 | 64.24 |
| Gender: % males | 86 | 59 |
| Questionnaire data | Cases | Controls |
|---|---|---|
| Demographics (age, sex, ethnicity, region, education etc..) | x | x |
| Active smoking | x | x |
| Passive smoking | - | - |
| Occupational exposures | x | x |
| Residential history | x | x |
| Water chlorination byproducts | - | - |
| Arsenic exposure | x | x |
| Other environmental exposures | x | x |
| Hair dye use | - | - |
| Drug use | - | - |
| Medical History | x | x |
| Family History | x | x |
| Quality of life | - | - |
| Diet/nutrition | x | x |
| Caffeine intake | x | x |
| Fluid intake | x | x |
| Urine pH measurements | - | - |
| Other information, please specify | - | - |
| Biological Samples | Cases | Controls |
|---|---|---|
| Blood DNA | x | x |
| Buccal DNA | x | x |
| Serum/plasma | x | - |
| Cryopreserved whole blood / lymphocytes | - | - |
| Red blood cells | - | - |
| Urine samples | - | - |
| Toenail clippings | - | - |
| Others, please specify | - | - |
| Paraffin tissue blocks | - | |
| Frozen tissue | - |
| For Cases Only | |
| Information at time of diagnosis | Cases |
|---|---|
| Histological confirmation | x |
| Number of tumors | - |
| Tumor site | x |
| Tumor size | - |
| Tumor grade | - |
| Growth pattern | - |
| Treatment of primary tumor | - |
| Stage | - |
| Other information, please specify | - |
| Follow-up information | Cases |
|---|---|
| Treatment information | - |
| Tumor recurrence | - |
| Tumor progression | - |
| Survival | - |
| Histological confirmation | - |
| Number of tumors | - |
| Tumor site | - |
| Tumor size | - |
| Tumor grade | - |
| Growth pattern | - |
| Stage | - |
| Active smoking | - |
| Occupational exposures | - |
| Drug use | - |
| Medical History | - |
| Quality of life | - |
| Caffeine intake | - |
| Fluid intake | - |
| Other information , please specify | - |